Abas7
Thanks for your insights and facts based on published documents. It is nice to see the positives among all the gloom and doom. I do hope we have some sensational figures at ASCO which give the first clues that Cvav will dwarft provenge.
Lucy said in an interview that Martin was good for the corporatwe stage ( cap raising, nasdaq, etc) whereas Matthew Lehman is apt for the operational stage because of his extensive experience in clinical trials.
Brainy
reversal and upcoming newsflow, page-2
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
0.005(1.27%) |
Mkt cap ! $588.3M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 41.0¢ | 38.5¢ | $952.5K | 2.391M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 140466 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 231265 | 14 |
View Market Depth
| Last trade - 13.17pm 03/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |